TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis

TiGenix NV , the European leader in cell therapy, announced today that it will develop its intravenous-administered allogeneic stem cell product, Cx611, for patients suffering from early rheumatoid arthritis and for patients suffering from severe sepsis, a potentially life-threatening complication of infection.

http://ift.tt/V0TpXU